Fed. Circ. Nixes Abraxis Win In Naropin Patent Row

Law360, New York (November 10, 2010, 3:35 PM ET) -- A federal appeals court has overturned a lower court's ruling that generic-drug maker Navinta LLC infringed three patents for Abraxis BioScience Inc.'s injectable pain management drug Naropin.

A divided three-judge panel for the U.S. Court of Appeals for the Federal Circuit ruled Tuesday that a district court should have granted Navinta's motion to dismiss because Abraxis did not technically hold title over the patents when it filed suit in March 2007.

Abraxis had agreed to buy the patents covering Naropin from AstraZeneca PLC in 2006, but...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required